Multiple Firsts As Pexidartinib Approved In US - With Warning
Executive Summary
Further progress for Daiichi Sankyo's strategic push into oncology as US issues first approval globally for first-in-class rare disease drug Turalio - but with liver toxicity safeguards.
You may also be interested in...
Deciphera’s Vimseltinib Could Benefit From Liver Safety, Prescriber Overlap in TGCT
Positive topline results from the Phase III MOTION trial showed none of the liver toxicity that earned Daiichi Sankyo’s Turalio a boxed warning and REMS in tenosynovial giant cell tumor.
Keeping Track: FDA OKs AMAG's Vyleesi, But Bronchitol And Quizartinib Draw CRLs
The latest drug development news and highlights from our US FDA Performance Tracker.
Defining REMS Success An Unanswered Question For Daiichi's Pexidartinib
US FDA still deliberating on how best to measure success of the liver safety program for Daiichi's TGCT treatment, but REMS will probably assess both process and outcomes.